Osteoarthritis Gene Therapy Market Size

Osteoarthritis Gene Therapy Market size was valued at USD 8.07 billion in 2024 and is likely to cross USD 21.68 billion by 2037, expanding at more than 7.9% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of osteoarthritis gene therapy is estimated at USD 8.61 billion.

The growth of the market can be attributed to the ease of administration, affordable pain medication and therapy, and rising incidents of osteoarthritis diseases across the globe. Moreover, it is believed that 40 to 65% of osteoarthritis includes genetic components. Additionally, significant growth in the geriatric population is also anticipated to influence the growth of the market positively. A study conducted by United Nations (UN) in 2019 stated that 703 million people are aged 65 years or over. Furthermore, a large portion of the global population showed an affirmative response toward gene therapy to treat osteoarthritis disease owing to its high effectiveness. As per a report published by Yale University, a significant surge in patients receiving gene therapy is projected to reach the number of 1.09 million over the forecast period. These factors are anticipated to boost the growth of the global osteoarthritis gene therapy market.